We demonstrated that (i) IRE-ablation was capable of reducing lung cancer burden through its efficient induction of tumor cell apoptosis and the release of large amounts of TAs and DAMP adjuvants, and (ii) 41BB-agonist signaling in Combo potentiates the therapeutic efficacy of IRE+Combo ablation in eradicating local s.c. 3LLOVA cancer and lung BLOVA metastasis by promoting responses from CD8+, CD103+ and unexpected CD8+CD103+ cDC1 subsets as well as CD103+TCF1+ TRM cells in TDLNs (Figure 9). Here, CD8A is linked to lung carcinoma.